Table 2.
Subgroup analyses of the highest post-diagnostic aspirin exposure and prostate cancer-specific mortality risk.
| Group | OR(95%CI) | Number of studies | I2 (%) | P(heterogeneity) |
|---|---|---|---|---|
| Region | ||||
| America | 0.81(0.65,1.03) | 9 | 48.1 | 0.052 |
| Europe | 1.12(0.88,1.41) | 4 | 54.1 | 0.088 |
|
| ||||
| Study type | ||||
| case-control | 1.31(0.85,2.01) | 1 | NA | NA |
| cohort | 0.89(0.74,1.07) | 12 | 57.8 | 0.006 |
|
| ||||
| Participants | ||||
| 0.91(0.74,1.11) | 8 | 41.7 | 0.100 | |
| 0.92(0.65,1.28) | 5 | 70.8 | 0.008 | |
|
| ||||
| Age | ||||
| 0.51(0.32,0.80) | 4 | 0 | 0.417 | |
| 0.98(0.79,1.21) | 5 | 67 | 0.017 | |
|
| ||||
| Follow-up time | ||||
| 0.89(0.76,1.05) | 4 | 0 | 0.392 | |
| 0.96(0.74,1.24) | 7 | 60.5 | 0.019 | |
|
| ||||
| Quality∗ | ||||
| moderate | 0.55(0.29,1.05) | 4 | 66.4 | 0.030 |
| high | 1.01(0.84,1.21) | 9 | 49.5 | 0.045 |
|
| ||||
| Adjusted for smoking | ||||
| yes | 0.96(0.71,1.31) | 5 | 70.3 | 0.009 |
| no | 0.97(0.79,1.18) | 7 | 31.3 | 0.189 |
|
| ||||
| Adjusted for cardiovascular events | ||||
| yes | 0.96(0.72,1.27) | 6 | 64.6 | 0.015 |
| no | 0.96(0.78,1.19) | 6 | 37.4 | 0.157 |
∗A total score of 4-6 was considered moderate quality, and 7-9 was deemed high quality.